A presentation titled “The First Experience of Using the Human Acellular Vessels in Ukraine for the Treatment of Patients with Vascular Trauma” was given this week at @ESVSmembership's #ESVS2022 meeting. Read more about the talk here: https://t.co/K9FIM5Bg40
We're thrilled to announce the appointment of two distinguished healthcare professionals. Lt. General Bruce Green, M.D., joins as a member of the Board of Directors, and pharma industry veteran Cindy Cao joins as a member of our Leadership Team. Read more: https://t.co/EASyKxYYEP
$HUMA management will host a webcast and conference call on Friday, August 12, 2022 at 8:00 A.M. ET to provide a corporate and financial update. Read more here: https://t.co/w1zX4IMHxT
Our 3.5mm #HAV™ was observed to maintain structural integrity & patency for up to six months post-implantation & showed evidence of robust host cell repopulation and remodeling. Results presented at #BCVS by Dr. Adam Williams, @DukeU. Read more: https://t.co/cDCvIzVJ7g
@Erin_Harris1, appreciate the opportunity to share my experience & thoughts with @_CellandGene on what it takes to change the way we think about #science, tissue #engineering, and the way patients are treated thanks to advancements in #regenmed capabilities!
6-month outcomes from a preclinical study of $HUMA small diameter HAVs in coronary artery bypass grafting will be presented next week at the @American_Heart Basic Cardiovascular Sciences (#BCVS) Scientific Sessions taking place in Chicago, IL. Learn more: https://t.co/G6l4DsUl6D
Join us for a KOL Webinar on $HUMA's HAV™ in the Treatment of Vascular Trauma feat. @KeckMedUSC Dr. @gregamagee, and @DenverHealthMed Dr. Ernest E. Moore. Live Q&A will follow, click here to learn more & register: https://t.co/VIjnQ2DchK
The @JAMASurgery#manuscript by @alexislauria1 and @trasmussen_md reviews the clinical need for improved options for vascular reconstruction, and the potential advantages of the #HAV over existing approaches. Read more: https://t.co/yV6Ue5Gva6
We’re thrilled to welcome Diane Seimetz, PhD, to the $HUMA Board of Directors. Her expertise will be invaluable as we move towards the commercialization of our HAV™. Learn more about Dr. Seimetz here: https://t.co/G4uMzl7E7X
The first Ukrainian patients have received implants of our HAV for the treatment of vascular trauma injuries as part of our humanitarian relief initiative to provide investigational HAVs to multiple front-line Ukrainian hospitals. Read more here: https://t.co/hCAkGkeRSp
Humacyte works hard to embed diversity, equality and inclusion education in every employee's journey. We honor #Juneteenth2022, and encourage time for reflection and activism to inspire positive change in our communities.
We're back in Boston this week at @VascularSVS#VAM22 - if you're attending, be sure to visit us on the expo floor at booth 116 to meet our team and get a first-hand look at our #HAV!
Special thanks to @maggienewland and @WNCN for last night's coverage of the humanitarian effort to provide our HAVs to the people of #Ukraine. In case you missed it, check it out here:
https://t.co/XyTPlIlPyz
Our team is attending @MTEC_SC in Baltimore today to discuss advancing technologies in biomedicine and creating new possibilities for treatment at the point of injury for warfighters.
I'm incredibly proud of the @Humacyte team for contributing to ongoing medical care in Ukraine, and for supporting patients and healthcare professionals on the ground during this humanitarian crisis.
We are thrilled to report that our shipment of HAVs has safely arrived in the hands of brave medical professionals in @Ukraine. It is truly an honor to provide these potentially life-saving vessels in this humanitarian effort to aid in medical relief during these conflicts.
Humacyte has worked with the @US_FDA Office of International Programs and @Ukraine Ministry of Health to coordinate the import of our HAV™ to six hospitals in #Ukraine for treatement of wounded civilians and soldiers. Read more about our efforts here: https://t.co/O9j2GiL7lc
We're thrilled to welcome Dr. Shamik Parikh as our new Chief Medical Officer! He will lead $HUMA's global clinical development strategy, including oversight of the preclinical and clinical development, clinical operations, and #medical affairs functions. https://t.co/CagRiFk7sD
We’re thrilled to see Dr. Danielle Mitchell celebrating 3 years since receiving her #HAV. She says, “the future of #medicine is happening now, and to be a part of this is just incredible.” Be sure to check out the @NBC15_madison interview!